

SECTION A

CERTIFICATE & LICENCE

CHỨNG NHẬN & GIẤY PHÉP

Our certifications reflect our dedication to quality, safety and regulatory compliance across all aspects of our operations. Empowering innovation through trust and excellence.

Các chứng nhận của chúng tôi thể hiện cam kết về chất lượng, an toàn và tuân thủ các quy định trong mọi hoạt động vận hành. Thúc đẩy đổi mới dựa trên sự tin cậy và tiêu chuẩn xuất sắc.



CERTIFICATE / CHỨNG NHẬN

WHO - GMP

Good Manufacturing Practice

Thực Hành Sản Xuất Tốt

CERTIFICATION DETAILS THÔNG TIN CHỨNG NHẬN

Certificate Name / Tên chứng nhận

WHO-GMP
Good Manufacturing Practice

Certificate No. / Chứng nhận số

12812

Issue Date / Ngày phát hành

04/11/2025

Validity / Có hiệu lực

04/11/2025 - 16/10/2028

About / Mô tả

WHO-GMP is a quality assurance system for manufacturers of pharmaceuticals, biologics, and advanced therapy products. It ensures that products are consistently produced and controlled according to quality standards appropriate to their intended use and in compliance with regulatory requirements.

WHO-GMP là hệ thống đảm bảo chất lượng dành cho các cơ sở sản xuất dược phẩm, chế phẩm sinh học và các sản phẩm trị liệu tiên tiến. Tiêu chuẩn này đảm bảo sản phẩm được sản xuất và kiểm soát một cách nhất quán theo các yêu cầu chất lượng phù hợp với mục đích sử dụng và tuân thủ các quy định của cơ quan quản lý.

Certificate

No. 12812



ReeLabs Private Limited

CTS No- 1627/A, S.No-169 (pt), Royal Palms, Aarey Colony,
Goregaon East, Mumbai-400065 India

QS Zürich AG certifies that the management system of the above mentioned company and above mentioned location has been evaluated and meets the requirements established by the following rules:

WHO-GMP

The management system includes:

Collection, processing, enrichment and storage of stem cells, growth factors, actives and exosomes derived from foetus, placenta, amnion, umbilical cord, cord blood, bone marrow, tooth, fat, menstrual fluid, hair follicle and adult tissue, along with related R&D, publications, patents, clinical trials, product development and therapies.

During the period of validity of this certificate, the management system of the company must always comply with the requirements of the certified standards.

For updated amendments within the scope of certification of the present certificate, please refer to <https://www.quality-service.ch/>

Previous cycle until:	16.10.2025
Start current cycle:	17.10.2025
Recertification audit:	09.10.2025
First certification date:	24.10.2016
Validity (Subject to successful surveillance audit):	04.11.2025 - 16.10.2028


04.11.2025, Management

CERTIFICATE / CHỨNG NHẬN

GLP

Good Laboratory Practices

Thực Hành Phòng Thí Nghiệm Tốt



CERTIFICATION DETAILS THÔNG TIN CHỨNG NHẬN

Certificate Name / Tên chứng nhận

GLP
Good Laboratory Practices

Certificate No. / Chứng nhận số

12813

Issue Date / Ngày phát hành

04/11/2025

Validity / Có hiệu lực

04/11/2025 - 16/10/2028

About / Mô tả

GLP is a quality management system for non-clinical laboratory studies. It ensures that research, testing, and analytical activities are conducted, monitored, recorded, and reported according to internationally recognized standards, ensuring the reliability, integrity, and traceability of scientific data.

GLP là hệ thống quản lý chất lượng dành cho các nghiên cứu và thử nghiệm trong phòng thí nghiệm. Tiêu chuẩn này đảm bảo các hoạt động nghiên cứu, phân tích và kiểm nghiệm được thực hiện, giám sát, ghi nhận và báo cáo theo các tiêu chuẩn quốc tế, nhằm đảm bảo tính chính xác, độ tin cậy và khả năng truy xuất của dữ liệu khoa học.

Certificate

No. 12813



ReeLabs Private Limited

CTS No- 1627/A, S.No-169 (pt), Royal Palms, Aarey Colony,
Goregaon East, Mumbai-400065 India

QS Zürich AG certifies that the management system of the above mentioned company and above mentioned location has been evaluated and meets the requirements established by the following rules:

Good Laboratory Practices (GLP)

The management system includes:

Collection, processing, enrichment and storage of stem cells, growth factors, actives and exosomes derived from foetus, placenta, amnion, umbilical cord, cord blood, bone marrow, tooth, fat, menstrual fluid, hair follicle and adult tissue, along with related R&D, publications, patents, clinical trials, product development and therapies.

During the period of validity of this certificate, the management system of the company must always comply with the requirements of the certified standards.

For updated amendments within the scope of certification of the present certificate, please refer to <https://www.quality-service.ch/>

Previous cycle until:	16.10.2025
Start current cycle:	17.10.2025
Recertification audit:	09.10.2025
First certification date:	24.10.2016
Validity (Subject to successful surveillance audit):	04.11.2025 - 16.10.2028




04.11.2025, Management

CERTIFICATE / CHỨNG NHẬN

ISO 9001:2015

Quality Management System

Hệ Thống Quản Lý Chất Lượng



CERTIFICATION DETAILS THÔNG TIN CHỨNG NHẬN

Certificate Name / Tên chứng nhận
ISO 9001:2015

Certificate No. / Chứng nhận số
12811

Issue Date / Ngày phát hành
04/11/2025

Validity / Có hiệu lực
04/11/2025 - 16/10/2028

About / Mô tả

ISO 9001:2015 is an internationally recognized Quality Management System standard. It ensures that processes are consistently managed, monitored, and improved to deliver high-quality products and services while meeting customer and regulatory requirements.

ISO 9001:2015 là tiêu chuẩn quốc tế về Hệ thống Quản lý Chất lượng. Tiêu chuẩn này đảm bảo các quy trình được quản lý, giám sát và cải tiến một cách nhất quán nhằm cung cấp sản phẩm và dịch vụ chất lượng cao, đồng thời đáp ứng yêu cầu của khách hàng và cơ quan quản lý.

Certificate

No. 12811



ReeLabs Private Limited

CTS No- 1627/A, S.No-169 (pt), Royal Palms, Aarey Colony,
Goregaon East, Mumbai-400065 India

QS Zürich AG certifies that the management system of the above mentioned company and above mentioned location has been evaluated and meets the requirements established by the following rules:

ISO 9001: 2015

The management system includes:

Collection, processing, enrichment and storage of stem cells, growth factors, actives and exosomes derived from foetus, placenta, amnion, umbilical cord, cord blood, bone marrow, tooth, fat, menstrual fluid, hair follicle and adult tissue, along with related R&D, publications, patents, clinical trials, product development and therapies.

During the period of validity of this certificate, the management system of the company must always comply with the requirements of the certified standards.

For updated amendments within the scope of certification of the present certificate, please refer to <https://www.quality-service.ch/>

Previous cycle until:	16.10.2025
Start current cycle:	17.10.2025
Recertification audit:	09.10.2025
First certification date:	24.10.2016
Validity (Subject to successful surveillance audit):	04.11.2025 - 16.10.2028




04.11.2025, Management

REGULATORY LICENSES / GIẤY PHÉP HOẠT ĐỘNG

FDA MAHARASHTRA LICENSE

Food & Drugs Administration (India)

Cơ Quan Quản Lý Thực Phẩm Và Dược Phẩm (Ấn Độ)



REGULATORY LICENSE THÔNG TIN GIẤY PHÉP

License Name / Tên giấy phép

FDA MAHARASHTRA STATE LICENSE

Certificate No. / Chứng nhận số

28F-MH/103124

Issue Date / Ngày phát hành

04/06/2025

Validity / Có hiệu lực

09/08/2024 – 08/08/2029

About / Mô tả

The FDA Maharashtra State License is issued by the Food & Drugs Administration, Maharashtra State, India. It authorizes ReeLabs to process, cryopreserve and store umbilical cord blood stem cells in compliance with applicable regulatory requirements. The license confirms that the facility is approved to operate cord blood banking activities under the supervision of the relevant health authority.

Giấy phép **FDA Maharashtra State** được cấp bởi Cục Quản lý Dược và Thực phẩm bang Maharashtra, Ấn Độ. Giấy phép này cho phép ReeLabs thực hiện hoạt động thu thập, xử lý, bảo quản lạnh và lưu trữ tế bào gốc máu cuống rốn theo các yêu cầu pháp lý hiện hành. Đây là sự xác nhận rằng cơ sở được phép vận hành hoạt động ngân hàng máu cuống rốn dưới sự giám sát của cơ quan quản lý y tế có thẩm quyền.

Regulatory Approval

License renewal approved by the Drug Controller General of India (DCGI) for the period 09 August 2024 to 08 August 2029.

Việc gia hạn giấy phép đã được Tổng cục Kiểm soát Dược phẩm Ấn Độ (DCGI) phê duyệt cho giai đoạn từ ngày 09/08/2024 đến ngày 08/08/2029.

**Food & Drugs Administration (Maharashtra State)**

Letter No: MH/MZ6/RNW/28F-MH/103124
 Food & Drugs Administration, MUMBAI Division
 Bandra Kurla Complex
 Bandra East
 Mumbai - 400051

License Renewal With Products

Validity Period: 09/08/2024 To 08/08/2029

To :

LICENSE No : 28F-MH/103124

& Dt : 04/06/2025

755242- REELABS PVT.LTD (Private Limited)
 CTS NO. 1627/A, S.NO. 169 (PT.) OF VILLAGE MAROL MAROSHI,, ROYAL
 PALMS, AAREY COLONY, GOREGAON EAST, MUMBAI - 400065
 Taluka: GOREGAON EAST, District: Mumbai-Zone6

Sir,

Ref :- Your Inward Application vide Inward ID:- 267261 (RNW) Dated :- 13/07/2024

With reference to your Inward application, we inform you that your said application is considered & following
LICENSE has been **RENEWED**

Type		Form	LIC No / Validity	First Issue / Rnw
Own: At my OWN Manufacturing Premises		28F	MH/103124 08/08/2029	09/08/2019 09/08/2024
Prod	Name of Drugs			
1. 753938	Umbilical Cord Blood Stem Cells			Domestic
PAN No.	Staff Name	Section	Designation	Qual
*****946N	ABHIJIT S BOPARDIKAR	Cord blood processing & cryogenic storage	Medical Director	MDP
*****736A	DHANASEKARAN MARAPOUNDER	Cord blood processing & cryogenic storage	TECHNICAL SUPERVISOR	PHD
*****824P	NEHA ASHOKKUMAR DUBEY	Cord blood processing & cryogenic storage	Cord Blood Technician	MSC
*****174A	RAGHWENDRA KUMAR	Haematology & serology lab, Transfusion transmissible diseases screening laboratory, Sterility testing laboratory	Lab Incharge	MSC
*****264E	RAVINDRA S. KHAIRE	Cord blood processing & cryogenic storage	Cord Blood Bank Technician	BSC
*****192H	ROSY THOMAS	Cord blood processing & cryogenic storage	Cord Blood Bank Technician	MTL
*****601M	SAGARIKA MISHRA	Cord blood processing & cryogenic storage	Cord Blood Technician	MSC

This License has been **RENEWED** wef 09/08/2024 and valid up to 08/08/2029**Terms and Conditions**

- 1) Licensee should comply with all the provisions of Drugs & Cosmetics Act, 1940 & Rules 1945 as amended up to dt.
- 2) Licensee should comply with all the provisions of Drugs (Price Control) Order 2013 as amended up to dt (wherever applicable).
- 3) Licensee should abide by all the provisions of Drugs & Magic Remedies (Objectionable Advertisement) Act, 1954 & Rules 1955 as amended up to date
- 4) Licensee should not manufacture any drug/cosmetic by a name belonging to another manufacturer
- 5) Licensee should not manufacture or sell drugs/cosmetics even if it is included in the approved list of product, if it is or as and when banned by Licensing Authority or Drugs Controller General of India or Government of India.
- 6) The permission is granted subject to the condition that, the product is safe, for use in context of pharmaceutical Aids, Additions and excipient used in the formulation
- 7) Any addition thereto or any deletion therefore will not be carried out without permission of Licensing Authority

Fee Payment(s) : DB-Id: 678969 - 13/07/2024 (Amt: 7500) (LICENSE RENEWAL), DB-Id: 734723 - 04/06/2025 (Amt: 6000) (RENEWAL FEE)
 Balance : 4200

This License/Certificate is eSIGNED. Physical Signature is NOT Required

No. of Products: 1, No. of Ingredients: 1

Division	MFG ID No	Type: License Renewal	License No	Issue Date
MUMBAI (MZ6)	755242	RNW-267261-13/07/2024	28F-MH/103124	04/06/2025

For online Third Party Approval Verification: Go to fdamfg.maharashtra.gov.in & Click TPAV Pg: 1/2 05/06/25

SECTION B

PATENT PORTFOLIO

DANH MỤC SÁNG CHẾ

Our patented technologies represent breakthrough innovations in biotechnology, cell preservation, regenerative medicine and advanced therapeutic applications.

Các công nghệ được cấp bằng sáng chế của chúng tôi đại diện cho những đột phá trong lĩnh vực công nghệ sinh học, lưu trữ tế bào, y học tái tạo và các ứng dụng điều trị tiên tiến.

INTELLECTUAL PROPERTY

SỞ HỮU TRÍ TUỆ

13

PATENTS
BẰNG SÁNG CHẾ

3

JURISDICTIONS
PHẠM VI BẢO HỘ



UNITED STATES PATENT
SÁNG CHẾ ĐƯỢC BẢO HỘ TẠI HOA KỲ



EUROPEAN PATENT
SÁNG CHẾ ĐƯỢC BẢO HỘ TẠI CHÂU ÂU



INDIAN PATENT
SÁNG CHẾ ĐƯỢC BẢO HỘ TẠI ẤN ĐỘ

(12) United States Patent (10) Patent No.: US 2023/0210747 A1
(45) Date of Patent: Jul. 6, 2023

(54) ANTI-AGEING COSMETIC COMPOSITIONS FOR MEN AND WOMEN, CONTAINING BIOACTIVE PROTEIN, AND THE METHOD OF ITS PRODUCTION

(71) Applicant: REELABS BIOTECHNOLOGY PTE. LTD.

(72) Inventors: Abhijit Bopardikar; Oleksandr Kukharchuk; Padma Priya Anand Baskaran; Andrii Kukharchuk; Sunil Pophale; Rohit Kalkarni

Fig. 1






Fig. 2



PATENT 01

BẰNG SÁNG CHẾ 01



UNITED STATES PATENT

Anti-Ageing Cosmetic Compositions for Men and Women, Containing Bioactive Protein, and the Method of its Production

Các chế phẩm mỹ phẩm chống lão hóa dành cho nam và nữ, chứa protein hoạt tính sinh học và quy trình sản xuất



PUBLICATION NUMBER
20230210747



PUBLICATION DATE
06/07/2023



PATENT TYPE
United States

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



Oleksandr Kukharchuk



Padma Priya Anand Baskaran



Andrii Kukharchuk



Sunil Pophale



Rohit Kulkarni

PATENT 02

BẰNG SÁNG CHẾ 02



UNITED STATES PATENT

Cytoprotective compositions for short-term cells storage and transportation without cryopreservation and deep freezing

Các chế phẩm bảo vệ tế bào phục vụ lưu trữ và vận chuyển tế bào ngắn hạn mà không cần bảo quản lạnh đông hoặc đông lạnh sâu

PUBLICATION NUMBER
20230056314PUBLICATION DATE
23/02/2023PATENT TYPE
United States

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



Oleksandr Kukharchuk



Padma Priya Anand Baskaran



Andrii Kukharchuk



Sunil Pophale



Rohit Kulkarni

PATENT 03

BẰNG SÁNG CHẾ 03



UNITED STATES PATENT

The Method Of Autologous Primary Hair Follicles Preparation In 3D Culture

Phương pháp tạo lập nang tóc nguyên phát tự
thân trong môi trường nuôi cấy 3D



PUBLICATION NUMBER
12.234.478 B2



PUBLICATION DATE
25/02/2025



PATENT TYPE
United States

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



Oleksandr Kukharchuk



Padma Priya Anand Baskaran



Andrii Kukharchuk



Sunil Pophale



Rohit Kulkarni



The
United
States
of
America



UNITED STATES PATENT

Granted on February 25, 2025 to

Dr. Abhijit Bopardikar

- INVENTOR -


Patent No. US 12,234,478 B2 METHOD OF AUTOLOGOUS PRIMARY HAIR FOLLICLES PREPARATION IN 3D CULTURE

Abhijit Bopardikar, Oleksandr Kukharchuk, Padma Priya Anand Baskaran,
Andrii Kukharchuk, Sunil Pophale and Rohit R. Kulkarni, Inventors
Reelabs Pvt. Ltd., Assignee

This breakthrough invention introduces a novel approach to hair restoration, utilizing a proprietary 3D culture system to cultivate and multiply autologous human hair follicles. This technology employs a sandwich cultivation technique, wherein patient-derived hair follicle cells and scalp skin are carefully layered on a fibrin gel matrix infused with targeted growth factors.

Key Benefits:

1. Advanced, cutting-edge technology: The proprietary 3D culture system and fibrin gel matrix provide a unique environment for optimal hair follicle growth.
2. Enhanced hair growth: 20-fold-plus increase in the number of autologous hair follicles, offering a safe and permanent solution for hair loss and baldness.
3. Personalized treatment: Patient-specific approach ensures natural and tailored hair restoration.



The Director of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law. Therefore, this

United States Patent

grants to the persons(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America of importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, subject to the payment of maintenance fees as provided by law.

Coke Moya-Sneut



ReeLabs
Protect. Nurture. Cure

Acting Director of the United States Patent and Trademark Office

PATENT 04

BẰNG SÁNG CHẾ 04



EUROPEAN PATENT

The Method Of Autologous Primary Hair Follicles Preparation In 3D Culture

Phương pháp tạo lập nang tóc nguyên phát tự
thân trong môi trường nuôi cấy 3D



PUBLICATION NUMBER
EP3813952A1



PUBLICATION DATE
05/05/2021



PATENT TYPE
European

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



Oleksandr Kukharchuk



Padma Priya Anand Baskaran



Andrii Kukharchuk



Sunil Pophale



Rohit Kulkarni

PATENT 05

BẰNG SÁNG CHẾ 05



UNITED STATES PATENT

Foetal Polymix Of Mesenchymal Stem Cells Under Hypoxic Conditions For The Treatment Of Clinical Disorders

Hỗn hợp tế bào gốc trung mô nguồn gốc bào thai được nuôi cấy trong điều kiện thiếu oxy để điều trị các rối loạn lâm sàng

**PUBLICATION NUMBER**
US20210047614A1**PUBLICATION DATE**
18/02/2021**PATENT TYPE**
United States

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



ReeLabs Private Limited (IN)



Sunil Pophale



Rohit Kulkarni

PATENT 06

BẰNG SÁNG CHẾ 06

GOVERNMENT OF INDIA
PATENT

Method of progenitor cells isolation from diderent organs by natural destruction of extracellular matrix

Phương pháp phân lập tế bào tiền thân từ các cơ
quan khác nhau thông qua sự phân hủy tự nhiên
của chất nền ngoại bào

PUBLICATION NUMBER
201921017524PUBLICATION DATE
02/05/2019PATENT TYPE
Government Of India

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



Oleksandr Kukharchuk



Anand Baskaran Padma Priya



Andrii Kukharchuk



Sunil Pophale



Rohit Kulkarni

PATENT 07

BẰNG SÁNG CHẾ 07



GOVERNMENT OF INDIA
PATENT

The Method Of Autologous Primary Hair Follicles Preparation In 3D Culture

Phương pháp tạo lập nang tóc nguyên phát tự
thân trong môi trường nuôi cấy 3D



PUBLICATION NUMBER
201821017071



PUBLICATION DATE
07/05/2018



PATENT TYPE
Government Of India

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



Oleksandr Kukharchuk



Anand Baskaran Padma Priya



Andrii Kukharchuk



Sunil Pophale



Rohit Kulkarni





The Patent Office, Government Of India

Patent Certificate

(Rule 74 of The Patents Rules)

442695

201821017071

07/05/2018

REELABS PVT. LTD

It is hereby certified that a patent has been granted to the patentee for an invention entitled "*THE METHOD OF AUTOLOGOUS PRIMARY HAIR FOLLICLES PREPARATION IN 3D CULTURE*" as disclosed in the above mentioned application for the term of 20 years from the 7th day of May 2018 in accordance with the provisions of the Patents Act, 1970.

It is hereby certified that a patent has been granted to the patentee for an invention entitled "*THE METHOD OF AUTOLOGOUS PRIMARY HAIR FOLLICLES PREPARATION IN 3D CULTURE*" as disclosed in the above mentioned application for the term of 20 years from the 7th day of May 2018 in accordance with the provisions of the Patents Act, 1970.

Date of Grant : 03/08/2023

Note. - The fees for renewal of this patent, if it is to be maintained, will fall / has fallen due on 7th day of May 2020 and on the same day

in every year thereafter.

PATENT 08

BẰNG SÁNG CHẾ 08



UNITED STATES PATENT

Method of Progenitor Cells Isolation from Different Organs by Natural Destruction of Extracellular Matrix

Phương pháp phân lập tế bào tiền thân từ các cơ quan khác nhau thông qua sự phân hủy tự nhiên của chất nền ngoại bào



PUBLICATION NUMBER
US10745664 B2



PUBLICATION DATE
03/05/2018



PATENT TYPE
United States

INVENTORS / NHÂN SỰ

Abhijit Bopardikar



Oleksandr Kukharchuk



Padma Priya Anand Baskaran



Andrii Kukharchuk



Sunil Pophale



Rohit Kulkarni



The
United
States
of
America



UNITED STATES PATENT

Granted on August 18, 2020 to

ReeLabs Pvt. Ltd.

- ASSIGNEE -

Patent No. US 10,745,664 B2

METHOD OF PROGENITOR CELL ISOLATION FROM DIFFERENT ORGANS BY NATURAL DESTRUCTION OF EXTRACELLULAR MATRIX

Inventors: Abhijit Bopardikar, Rohit Kulkarni,
Sunil Pophale, Andrii Kukharchuk, Oleksandr Kukharchuk and
Padma Priya Anand Baskaran

A method of isolating progenitor cells from different organs of an aborted fetus by using natural collagenolytic, fibrinolytic and proteolytic activity of an autologous abortive placenta; the method comprising preparing a collagenolytic, fibrinolytic, and proteolytic fetal placenta extract by selecting chorionic villi tissue from the abortive placenta, incubating the tissue with PGF2 α for activation of proteolytic activity, homogenizing the tissue, incubating with trypsin for activation of collagenase activity followed by addition of trypsin inhibitor and isolating fetal progenitor cells from target organs of the aborted fetus by performing an in situ three open-loop perfusion process of a fetus blood vascular system of the aborted fetus, wherein the perfusion process comprises removing blood from the fetus vascular system.




FIG. 1 Three open-loops blood supply system of fetus organs perfusion in situ

The Director of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law. Therefore, this

United States Patent

grants to the persons(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America of importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, subject to the payment of maintenance fees as provided by law.

Andrii Kukharchuk

Director of the United States Patent and Trademark Office

ReeLabs
Protect. Nurture. Cure

PATENT 09

BẰNG SÁNG CHẾ 09



UNITED STATES PATENT

Foetal Polymix Of Mesenchymal Stem Cells Under Hypoxic Conditions For The Treatment Of Clinical Disorders and Diseases

Hỗn hợp tế bào gốc trung mô nguồn gốc bào thai được nuôi cấy trong điều kiện thiếu oxy để điều trị các rối loạn lâm sàng

**PUBLICATION NUMBER**
US11072776B2**PUBLICATION DATE**
27/07/2021**PATENT TYPE**
United States

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



ReeLabs Private Limited (IN)



Sunil Pophale



Rohit Kulkarni



The
United
States
of
America



UNITED STATES PATENT

Granted on July 27, 2021 to


ReeLabs Pvt. Ltd.

- ASSIGNEE -

Patent No. US 11,072,776 B2
FOETAL POLYMIX OF MESENCHYMAL
STEM CELLS UNDER HYPOXIC CONDITIONS
FOR THE TREATMENT OF CLINICAL
DISORDERS AND DISEASES

Abhijit Bopardikar, Rohit Kulkarni and Sunil Pophale, Inventors

A unique, proprietary invention comprising of collection, isolation, enrichment and co-culture of mesenchymal stem cells derived from, but not limited to, two or more products of conception viz. placenta, amnion, amniotic fluid, chorion and / or umbilical cord under hypoxic or normoxic conditions. The therapeutic administration of this product can be used in comprehensive treatment of a wide variety of disorders encompassing congenital, degenerative, developmental and malignant conditions. The said product is also employed in an approved and Clinical Trial Registry (CTR) registered clinical trial (CTRI/2020/08/027043) to conclusively mitigate the lethal cytokine storm associated with moderate to severe COVID-19 infections.



The Director of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law. Therefore, this

United States Patent

grants to the persons(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America of importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, subject to the payment of maintenance fees as provided by law.

Andrew Karm

Director of the United States Patent and Trademark Office

ReeLabs
Protect. Nurture. Cure

PATENT 10

BẰNG SÁNG CHẾ 10



EUROPEAN PATENT

Foetal Polymix Of Mesenchymal Stem Cells Under Hypoxic Conditions For The Treatment Of Clinical Disorders

Hỗn hợp tế bào gốc trung mô nguồn gốc bào thai được nuôi cấy trong điều kiện thiếu oxy để điều trị các rối loạn lâm sàng

**PUBLICATION NUMBER**
EP3140417B1**PUBLICATION DATE**
21/04/2021**PATENT TYPE**
European

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



ReeLabs Private Limited (IN)



Sunil Pophale



Rohit Kulkarni



Presented To
ReeLabs Pvt Ltd



(11) **EP 3 140 417 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
21.04.2021 Bulletin 2021/16

(21) Application number: **15789493.2**

(22) Date of filing: **08.05.2015**

(51) Int Cl.:
A61K 35/28 (2015.01) **A61K 35/50** (2015.01)
A61K 35/51 (2015.01) **C12Q 1/02** (2006.01)
C12N 5/073 (2010.01) **C12N 5/071** (2010.01)
C12N 5/0789 (2010.01) **C12N 5/0793** (2010.01)
C12N 5/077 (2010.01)

(86) International application number:
PCT/IN2015/000205

(87) International publication number:
WO 2015/170347 (12.11.2015 Gazette 2015/45)

(54) **FOETAL POLYMIX OF MESENCHYMAL STEM CELLS UNDER HYPOXIC CONDITIONS FOR THE TREATMENT OF CLINICAL DISORDERS**

FÖTUS-POLYMIX AUS MESENCHYMALEN STAMMZELLEN UNTER HYPOXISCHEN
BEDINGUNGEN ZUR BEHANDLUNG KLINISCHER STÖRUNGEN

POLYMIX FOETAL DE CELLULES SOUCHES MÉSENCHYMATEUSES PLACÉ DANS DES
CONDITIONS HYPOXIQUES EN VUE DU TRAITEMENT D'AFFECTIIONS CLINIQUES

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **09.05.2014 IN 1603MU2014**
09.01.2015 US 201562101908 P

(43) Date of publication of application:
15.03.2017 Bulletin 2017/11

(73) Proprietor: **Reelabs Private Limited**
Mumbai, Maharashtra 400001 (IN)

(72) Inventors:
• **ABHIJIT, Bopardikar**
Mumbai 400053 (IN)
• **ROHIT, Kulkarni**
Mumbai 400053 (IN)
• **SUNIL, Pophale**
Mumbai 400039 (IN)

(74) Representative: **FRKelly**
27 Clyde Road
Dublin D04 F838 (IE)

(56) References cited:
EP-A1- 2 368 974 EP-A2- 2 594 636
WO-A1-94/16099 WO-A1-2006/019357

WO-A1-2008/143578 WO-A1-2008/146991
WO-A1-2008/146992 WO-A1-2009/052132
WO-A1-2011/101834 WO-A1-2012/131618
WO-A1-2013/082417 WO-A1-2013/172793
WO-A2-03/042405 WO-A2-2005/001076
US-A- 5 906 915 US-A1- 2005 244 963
US-A1- 2007 015 278 US-A1- 2010 124 569
US-A1- 2012 225 096

- **CASTRECHINI, NM.:** 'Mesenchymal Stem Cells In Human Placental Chorionic Villi Reside In A Vascular Niche.' **PLACENTA** vol. 31, 2010, pages 203 - 212, XP026975309
- **Francisco Dos Santos ET AL:** "Ex vivo expansion of human mesenchymal stem cells: A more effective cell proliferation kinetics and metabolism under hypoxia", **Journal of Cellular Physiology**, vol. 223, no. 1, 1 April 2010 (2010-04-01), pages n/a-n/a, XP055567032, US ISSN: 0021-9541, DOI: 10.1002/jcp.21987
- **Hamid Abdollahi ET AL:** "The Role of Hypoxia in Stem Cell Differentiation and Therapeutics", **JOURNAL OF SURGICAL RESEARCH.**, vol. 165, no. 1, 1 January 2011 (2011-01-01), pages 112-117, XP055567036, US ISSN: 0022-4804, DOI: 10.1016/j.jss.2009.09.057

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 140 417 B1

PATENT 11

BẰNG SÁNG CHẾ 11

GOVERNMENT OF INDIA
PATENT

Foetal Polymix Of Mesenchymal Stem Cells Under Hypoxic Conditions For The Treatment Of Clinical Disorders and Diseases

Hỗn hợp tế bào gốc trung mô nguồn gốc bào thai được nuôi cấy trong điều kiện thiếu oxy để điều trị các rối loạn lâm sàng

PUBLICATION NUMBER
1603/MUM/2014PUBLICATION DATE
09/09/2014PATENT TYPE
Government Of India

INVENTORS / NHÂN SỰ



Abhijit Bopardikar



ReeLabs Private Limited (IN)



Sunil Pophale



Rohit Kulkarni



PATENT 12

BẰNG SÁNG CHẾ 12



GOVERNMENT OF INDIA
PATENT

REEVEDA by ReeLabs



PUBLICATION NUMBER
1436/ MUM/2011



PUBLICATION DATE
10/05/2011



PATENT TYPE
Government Of India

INVENTORS / NHÂN SỰ



Arun Deshpande

PATENT 13

BẰNG SÁNG CHẾ 12



GOVERNMENT OF INDIA
PATENT

Gift Of Life



PUBLICATION NUMBER
551/MUM/2010



PUBLICATION DATE
03/03/2010



PATENT TYPE
Government Of India

INVENTORS / NHÂN SỰ



Abhijit Bopardikar